A compound having the following structure:

##STR00001##

wherein: R.sup.1 is a linker having the formula —(CH.sub.2).sub.n-L.sup.1-, wherein L.sup.1 contains 1-6 carbon atoms and at least one —NH— linkage and at least one oxygen-containing or sulfur-containing linkage, and n is an integer of 0-3; R.sup.2 is a group having the formula —C(Y)-E, wherein Y is O or S, and E is a hydrocarbon group and either: (i) at least one carbon-carbon or carbon-nitrogen unsaturated bond or (ii) at least one alkyl halide group; R.sup.3 is selected from H, NR′.sub.2, NHC(O)R′, and —(CH.sub.2).sub.p-T, wherein T contains at least one —NH— linkage; R.sup.a, R.sup.b, R.sup.c, R.sup.d, R.sup.e, and R.sup.f are independently selected from of H, hydrocarbon groups containing 1-3 carbon atoms, fluorine atom, and chlorine atom; X is N or CR.sup.9, wherein R.sup.9 is selected from H, hydrocarbon groups containing 1-3 carbon atoms, fluorine atom, and chlorine atom; and pharmaceutically acceptable salts thereof.

A compound having the following structure:

##STR00001##

wherein: R.sup.1 is a linker having the formula —(CH.sub.2).sub.n-L.sup.1-, wherein L.sup.1 contains 1-6 carbon atoms and at least one —NH— linkage and at least one oxygen-containing or sulfur-containing linkage, and n is an integer of 0-3; R.sup.2 is a group having the formula —C(Y)-E, wherein Y is O or S, and E is a hydrocarbon group and either: (i) at least one carbon-carbon or carbon-nitrogen unsaturated bond or (ii) at least one alkyl halide group; R.sup.3 is selected from H, NR′.sub.2, NHC(O)R′, and —(CH.sub.2).sub.p-T, wherein T contains at least one —NH— linkage; R.sup.a, R.sup.b, R.sup.c, R.sup.d, R.sup.e, and R.sup.f are independently selected from of H, hydrocarbon groups containing 1-3 carbon atoms, fluorine atom, and chlorine atom; X is N or CR.sup.9, wherein R.sup.9 is selected from H, hydrocarbon groups containing 1-3 carbon atoms, fluorine atom, and chlorine atom; and pharmaceutically acceptable salts thereof.

Described herein, inter alia, are Nurr1 receptor modulators and uses thereof. In an aspect is provided a method for treating a disease associated with dysregulation and/or degeneration of dopaminergic neurons in the central nervous system of a subject in need thereof, the method including administering to the subject in need thereof a therapeutically effective amount of a compound described herein.

This invention is directed to anticancer compounds, pharmaceutical compositions comprising the same, methods of making anticancer compounds, and methods of treating cancer with compounds and pharmaceutical compositions.

An object of the invention is to provide a crosslinking agent with which a crosslinked polymer that suffers little coloring with the lapse of time and shows excellent viscosity stability is obtained. The crosslinking agent of the invention includes a compound which contains two or more alkylhydrazide groups represented by the following general formula (1). ##STR00001##
(In formula (1), R.sup.1 represents an alkyl group having 1-10 carbon atoms, and symbol * is a linking bond.)

An object of the invention is to provide a crosslinking agent with which a crosslinked polymer that suffers little coloring with the lapse of time and shows excellent viscosity stability is obtained. The crosslinking agent of the invention includes a compound which contains two or more alkylhydrazide groups represented by the following general formula (1). ##STR00001##
(In formula (1), R.sup.1 represents an alkyl group having 1-10 carbon atoms, and symbol * is a linking bond.)

Provided are a method for producing a peptide compound including a step of using a hydrazine derivative represented by Formula (1); a reagent for forming a protective group including the compound; and a hydrazine derivative. In Formula (1), a ring A represents an aromatic hydrocarbon ring or an aromatic heterocyclic ring, R represents a hydrogen atom, an amino protective group, an amino acid residue, or a peptide residue, k represents an integer of 1 to 5, n represents 1 or 2, and R.sup.A's each independently represent an aliphatic hydrocarbon group or an organic group having an aliphatic hydrocarbon group.

##STR00001##

Provided are a method for producing a peptide compound including a step of using a hydrazine derivative represented by Formula (1); a reagent for forming a protective group including the compound; and a hydrazine derivative. In Formula (1), a ring A represents an aromatic hydrocarbon ring or an aromatic heterocyclic ring, R represents a hydrogen atom, an amino protective group, an amino acid residue, or a peptide residue, k represents an integer of 1 to 5, n represents 1 or 2, and R.sup.A's each independently represent an aliphatic hydrocarbon group or an organic group having an aliphatic hydrocarbon group.

##STR00001##

The present invention relates to compounds of formula (I) and to pharmaceutical compositions containing them:

##STR00001##

wherein meanings of the substituents are indicated in the description.

Such compounds for use in the treatment of cancer and other diseases related to altered angiogenesis, such as arthritic pathology, diabetic retinopathy, psoriasis and chronic inflammatory disease, are also within the scope of the present invention.

Amide compounds are disclosed. Also disclosed are pharmaceutical compositions comprising the compounds as well as methods of treating neurodegenerative diseases that involve administering the compounds or pharmaceutical compositions to a subject.